Item 8.01 Other Events.

On April 24, 2023, Unity Biotechnology, Inc. ("UNITY" or the "Company") announced positive 48-week data from its Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). The Company will host a conference call today, Monday, April 24, 2023, at 8:00 a.m., Eastern Time, to discuss the data results.

A copy of the press release and the presentation that will be referenced during the conference call are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits

Exhibit No.   Description

99.1            Press release titled "UNITY Biotechnology Announces Positive 48-Week
              Results from Phase 2 BEHOLD Study of UBX1325 in Patients with Diabetic
              Macular Edema," dated April 24, 2023

99.2            Presentation of Unity Biotechnology, Inc. dated April 24, 2023

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses